Epigenetic Targets in Drug Discovery. Methods and Principles in Medicinal Chemistry - Product Image

Epigenetic Targets in Drug Discovery. Methods and Principles in Medicinal Chemistry

  • ID: 4517484
  • Book
  • 416 Pages
  • John Wiley and Sons Ltd
1 of 4
This broad view of epigenetic approaches in drug discovery combines methods and strategies with individual targets, including new and largely unexplored ones such as sirtuins and methyl–lysine reader proteins.

Presented in three parts – Introduction to Epigenetics, General Aspects and Methodologies, and Epigenetic Target Classes – it covers everything any drug researcher would need in order to know about targeting epigenetic mechanisms of disease.

Epigenetic Drug Discovery is an important resource for medicinal chemists, pharmaceutical researchers, biochemists, molecular biologists, and molecular geneticists.
Note: Product cover images may vary from those shown
2 of 4
Introduction to Epigenetics

GENERAL ASPECTS AND METHODOLOGY

Epigenetic inhibitors in cancer

Structural Biology of Epigenetic Targets

Computer–based approaches

Mass Spectrometry approaches

Peptide Microarrays for epigenetic targets

Target fishing and chemoproteomics

Chemical probe development

EPIGENETIC TARGET CLASSES

HDAC inhibitors

Sirtuins

Methyltransferases

Demethylases LSD1

JMJD

Histone Acetyltransferases

BRD Bromodomains

Methyl–Lysine Reader Proteins

DNA modifying enzymes

Parasitic Epigenetic Targets
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Wolfgang Sippl holds the chair in Medicinal Chemistry at the Institute of Pharmacy at the Martin Luther University Halle–Wittenberg. After studying pharmacy at Free University Berlin, he obtained his Ph.D. degree with Hans–Dieter Höltje at Düsseldorf University in 1997. After post–doctoral work with Camille Wermuth (Strasbourg University) he obtained his habilitation from Düsseldorf University in 2002. In 2003, he accepted the professorship at Halle, where he is mainly working in the areas of computer–based drug design, in particular for epigenetic targets. In 2001 he was awarded the innovation prize for medicinal/pharmaceutical chemistry by the German Chemical Society, GDCh.

Manfred Jung holds a Ph.D. in Pharmaceutical Chemistry from the University of Marburg. After post–doctoral work with Tony Durst at the University of Ottawa, he became group leader at Münster University in 1994, completing his habilitation in 2000. Three years later, he moved to Freiburg University, where he is now a full professor for Pharmaceutical Chemistry. The focus of his research is chemical epigenetics, including inhibitor development and screening methods for new bioactive compounds. He is currently the co–chairman of the SFB research project "Medical Epigenetics".
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll